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Maslinic acid alleviates ischemia/
reperfusion-induced inflammation 
by downregulation of NFκB-
mediated adhesion molecule 
expression
emmanuel Ampofo, Julian J. Berg, Michael D. Menger & Matthias W. Laschke
Ischemia/reperfusion (I/R)-induced inflammation is associated with enhanced leukocyte rolling, 
adhesion and transmigration within the microcirculation. these steps are mediated by hypoxia-
triggered signaling pathways, which upregulate adhesion molecule expression on endothelial cells and 
pericytes. We analyzed whether these cellular events are affected by maslinic acid (MA). Mitochondrial 
activity and viability of MA-exposed endothelial cells and pericytes were assessed by water-soluble 
tetrazolium (WST)-1 and lactate dehydrogenase (LDH) assays as well as Annexin V/propidium iodide (PI) 
stainings. Effects of MA on hypoxia and reoxygenation-induced expression of E-selectin, intercellular 
adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 were determined by flow 
cytometry. the subcellular localization of the NFκB subunit p65 was analyzed by immunofluorescence 
and Western blot. I/R-induced leukocytic inflammation was studied in MA- and vehicle-treated mouse 
dorsal skinfold chambers by intravital fluorescence microscopy and immunohistochemistry. MA did not 
affect viability, but suppressed the mitochondrial activity of endothelial cells. Furthermore, MA reduced 
adhesion molecule expression on endothelial cells and pericytes due to an inhibitory action on NFκB 
signaling. Numbers of adherent and transmigrated leukocytes were lower in post-ischemic tissue of 
MA-treated mice when compared to vehicle-treated controls. In addition, MA affected reactive oxygen 
species (ROS) formation, resulting in a diminished oxidative DNA damage. Hence, MA represents 
an attractive compound for the establishment of novel therapeutic approaches against I/R-induced 
inflammation.
Ischemia/reperfusion (I/R) is associated with hypoxia-induced cytokine release, which promotes the binding 
of leukocytes to the microvascular endothelium and their transmigration across the endothelial lining into the 
surrounding tissue1. This process is mediated by specific adhesion molecules on endothelial cells2 and pericytes3. 
The expression of these surface proteins is strictly regulated by the NFκB signaling pathway4. Several studies have 
demonstrated that I/R initiates the activation of this pathway, resulting in the degradation of the IκB-complex 
and translocation of the main NFκB-subunit p65 into the nucleus5–7. This, in turn, induces the expression of the 
adhesion proteins E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule 
(VCAM)-18–10.
The inhibition of the NFκB pathway is a promising approach to reduce inflammatory reactions. In the last 
years, several phytochemical compounds have been identified, which are capable of suppressing the activity of 
this pathway, such as apocyanin, curcumin and maslinic acid (MA)11–13. MA can be found in fruits and veg-
etables, particularly in the skin of olives14. Several studies reported potent anti-tumor15,16, anti-oxidant17 and 
anti-inflammatory18–20 effects of MA. These are mediated by inhibitory actions of MA on the activity of pro-
tein kinase (PK)C and the NFκB pathway and stimulatory actions on heme oxygenase (HO)-1 and endothelial 
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nitric oxide synthase (eNOS), which suppresses the synthesis of important cytokines and reactive oxygen species 
(ROS)13,21,22.
These findings indicate that MA may also be capable of alleviating I/R-induced inflammation by downregu-
lation of NFκB-triggered endothelial and pericyte adhesion molecule expression. To test this hypothesis, we first 
determined in vitro the viability, adhesion molecule expression and subcellular localization of p65 in vehicle- and 
MA-treated endothelial cells and pericytes under hypoxia and reoxygenation. In addition, we analyzed in vivo 
leukocyte rolling, adhesion and transmigration in dorsal skinfold chambers of vehicle- and MA-treated mice, 
which were exposed to I/R.
Results
Effect of MA on mitochondrial activity and viability of endothelial cells. Vehicle- and MA-treated 
human dermal microvascular endothelial cells (HDMEC) were cultivated under hypoxia and reoxygenation to 
mimic I/R in vitro (Fig. 1a). Thereafter, we performed a water-soluble tetrazolium (WST)-1 assay and found that 
concentrations of MA ranging from 20–40 µM reduce the mitochondrial activity of HDMEC when compared to 
vehicle-treated controls (Fig. 1b). In contrast, MA treatment did neither result in an increase of lactate dehydroge-
nase (LDH) release (Fig. 1c) nor in a higher number of Annexin V/propidium iodide (PI)-positive cells (Fig. 1d). 
This indicates that MA dose-dependently affects the mitochondrial activity of endothelial cells without inducing 
apoptotic or necrotic cell death.
effect of MA on the expression of endothelial surface adhesion proteins and NFκB signaling. 
Next, we analyzed the expression of E-selectin, ICAM-1 and VCAM-1 during hypoxia and reoxygenation. 
Hypoxia and reoxygenation significantly increased the expression of these adhesion surface molecules (Fig. 2a–c). 
Figure 1. Effect of MA on mitochondrial activity and viability of endothelial cells. (a) Schematic illustration 
of the experimental hypoxia and reoxygenation setup to simulate I/R in vitro. (b,c) HDMEC were treated with 
vehicle (DMSO; white bars) or the indicated concentrations of MA (black bars) and cultivated for 16 h under 
normoxia or hypoxia. The cells were reoxygenated for 24 h and their mitochondrial activity and viability was 
assessed by a WST-1 (b) and a LDH assay (c). Hypoxia-exposed vehicle-treated cells were used as control and 
set 100% (n = 5). Lysed cells were used as positive control for the LDH assay (c, grey bar) (n = 5). Mean ± SD. 
*P < 0.05 vs. vehicle + hypoxia. (d) HDMEC were exposed to vehicle (DMSO) or MA (40 µM) and cultivated 
for 16 h under hypoxia. The cells were then reoxygenated for 24 h and Annexin V/PI-positive cells (% of gated 
cells) were assessed by flow cytometry (n = 5).
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Of interest, MA reduced dose-dependently the expression of E-selectin, ICAM-1 and VCAM-1 when compared 
to vehicle-treated controls (Fig. 2a–c). To investigate whether this effect is mediated by the inhibitory action of 
MA on NFκB, the cells were stimulated with tumor necrosis factor (TNF)-α, which specifically activates this 
pathway. This control experiment demonstrated indeed that the stimulatory effect of TNF-α on endothelial 
adhesion molecule expression is also suppressed by MA (Fig. 2d-f). Accordingly, we further determined the 
subcellular localization of the NFκB subunit p65 in HDMEC. Immunofluorescence analyses demonstrated an 
Figure 2. Effect of MA on the expression of endothelial surface adhesion proteins and NFκB signaling. (a–c) 
HDMEC were exposed to vehicle (DMSO; white bars) or the indicated concentrations of MA (black bars) 
and cultivated for 16 h under normoxia or hypoxia. The cells were then reoxygenated for 4 h or 24 h. The MFI 
of E-selectin (a) was assessed by flow cytometry after 4 h and the MFI of ICAM-1 (b) and VCAM-1 (c) was 
assessed by flow cytometry after 24 h. Hypoxia-exposed vehicle-treated cells were used as control and set 
100% (n = 5). Mean ± SD. *P < 0.05 vs. vehicle + hypoxia. (d–f ) HDMEC were exposed to vehicle (DMSO; 
white bars) or the indicated concentrations of MA (black bars) and cultivated for 24 h with or without TNF-
α. After 24 h, the expression of E-selectin (d), ICAM-1 (e) and VCAM-1 (f) was assessed by flow cytometry. 
Vehicle-treated, TNF-α-exposed cells were used as control and set 100% (n = 5). Mean ± SD. *P < 0.05 vs. 
vehicle + TNF-α. (g) Immunofluorescence images of vehicle (DMSO)- or MA (40 µM)-treated HDMEC, which 
were cultivated for 16 h under hypoxia. Thereafter, the cells were reoxygenated for 4 h and p65 was detected with 
an anti-p65 antibody. Scale bar: 50 µm. Images are representative of experiments conducted in triplicate. (h) 
HDMEC were exposed to vehicle (DMSO) or MA (40 µM) and cultivated as described in (g). The cytoplasmic 
and nuclear localization of p65 was analyzed by Western blot. Bands were cropped from different parts of the 
same gel. (i,j) p65/α-tubulin (% of vehicle + hypoxia) (i) and p65/nucleolin (% of vehicle + hypoxia) (j), as 
assessed by quantitative analysis of Western blots (n = 5). Mean ± SD. *P < 0.05 vs. vehicle + hypoxia.
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Figure 3. Effect of MA on mitochondrial activity, viability, ICAM-1 expression and NFκB signaling in 
pericytes. (a) Pericytes were characterized by NG2 and PDGFR-β expression. Scale bar: 50 µm. (b,c) Pericytes 
were treated with vehicle (DMSO; white bars) or the indicated concentrations of MA (black bars) and cultivated 
for 16 h under normoxia or hypoxia. The cells were reoxygenated for 24 h and their mitochondrial activity and 
viability were assessed by a WST-1 (b) and a LDH assay (c). The hypoxia-exposed vehicle-treated cells were used 
as control and set 100% (n = 5). Lysed cells were used as positive control for the LDH assay (c, grey bar) (n = 5). 
Mean ± SD. *P < 0.05 vs. vehicle + hypoxia. (d) Pericytes were exposed to vehicle (DMSO) or MA (40 µM) and 
cultivated for 16 h under hypoxia. The cells were then reoxygenated for 24 h and Annexin V/PI-positive cells 
(% of gated cells) were assessed by flow cytometry (n = 5). (e) Pericytes were cultivated as described in (b,c) 
and the MFI of ICAM-1 was assessed by flow cytometry. Hypoxia-exposed vehicle-treated cells were used as 
control and set 100% (n = 5). Mean ± SD. *P < 0.05 vs. vehicle + hypoxia. (f) Pericytes were exposed to vehicle 
(DMSO; white bars) or the indicated concentrations of MA (black bars) and cultivated for 24 h with or without 
TNF-α. The expression of ICAM-1 was assessed by flow cytometry. Vehicle-treated, TNF-α-exposed cells were 
used as control and set 100% (n = 5). Mean ± SD. *P < 0.05 vs. vehicle + TNF-α. (g) Immunofluorescence 
images of vehicle (DMSO)- or MA (40 µM)-treated pericytes, which were cultivated for 16 h under hypoxia and 
reoxygenated for 4 h. p65 was detected with an anti-p65 antibody. Scale bar: 50 µm. Images are representative 
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increased nuclear staining of p65 in the cells after hypoxia and reoxygenation (Fig. 2g). MA treatment attenuated 
the nuclear localization of the transcription factor when compared to vehicle-treated controls. These results could 
be confirmed by additional Western blot analyses, demonstrating an increased nuclear protein level of p65 in 
vehicle-treated HDMEC after hypoxia and reoxygenation and a significant reduction by MA exposure (Fig. 2h–j).
Effect of MA on mitochondrial activity, viability, ICAM-1 expression and NFκB signaling in pericytes. 
Besides endothelial cells, pericytes also crucially contribute to neutrophil crawling via the adhesion molecule 
ICAM-13. Therefore, we additionally assessed the effects of MA treatment on the viability and protein expression 
of human pericytes. For this purpose, they were first characterized by immunofluorescent detection of the typi-
cal surface proteins platelet-derived growth factor receptor (PDGFR)-β and nerve/glial antigen (NG)2 (Fig. 3a). 
Next, we could demonstrate that neither hypoxia and reoxygenation nor MA affect the mitochondrial activity 
of the cells and do not induce apoptotic or necrotic cell death (Fig. 3b–d). In addition, according to the results 
from the endothelial cell assays, hypoxia and reoxygenation- and TNF-α-induced ICAM-1 expression was also 
dose-dependently reduced by MA in pericytes when compared to vehicle-treated controls (Fig. 3e,f ). Further 
experiments with hypoxia and reoxygenation revealed that this was due to a prevention of shuttling of p65 into 
the nucleus (Fig. 3g–j).
Effect of MA on I/R-induced leukocyte-endothelial cell interaction. Based on our in vitro findings, 
we finally investigated the effects of MA on I/R-induced inflammation within a mouse dorsal skinfold chamber 
model (Fig. 4a,b). For this purpose, the animals were treated with doses of 10 mg/kg MA or 20 mg/kg MA i.p., 
which have already been shown to be effective in vivo23. Moreover, we treated the animals 19 h and 1 h before the 
induction of ischemia to ensure the inhibition of as many potential MA targets as possible.
First, we determined microhemodynamic parameters of those venules, which were used for the in vivo analy-
sis of leukocyte-endothelial cell interactions by means of intravital fluorescence microscopy. I/R induced vasodi-
lation in reperfused postcapillary and collecting venules in dorsal skinfold chambers of vehicle- and MA-treated 
mice, whereas centerline red blood cell (RBC) velocity, volumetric blood flow and wall shear rate of these ves-
sels were not affected by I/R (Table 1). Importantly, MA did not influence these parameters when compared to 
vehicle-treated mice (Table 1), indicating that the interaction of leukocytes with the microvascular endothelium 
could be investigated under comparable microhemodynamic conditions.
I/R did not affect the rolling of leukocytes in vehicle-treated mice and in animals receiving low dose MA 
(10 mg/kg) when compared to baseline values (Fig. 4c). In contrast, treatment of mice with high dose MA (20 mg/
kg) significantly increased the number of rolling leukocytes during post-ischemic reperfusion (Fig. 4c). In all 
groups, the number of adherent leukocytes was significantly elevated after I/R when compared to baseline condi-
tions (Fig. 4d). Interestingly, MA treatment significantly reduced the I/R-induced increase of leukocyte adherence 
in venules during the early post-ischemic reperfusion period (Fig. 4b,d).
We further analyzed the effects of I/R on the functional capillary density and macromolecular leakage within 
the dorsal skinfold chambers. As expected, I/R significantly decreased the functional capillary density and 
increased the macromolecular leakage (Fig. 4e,f). However, these parameters were not affected by MA (Fig. 4e,f).
Next, we investigated the expression of ICAM-1 and VCAM-1 in the dorsal skinfold chamber tissue after 3 h 
ischemia and 3 h reperfusion by means of Western blot (Fig. 5a,b). In line with our in vitro results, we found that 
the expression of these adhesion molecules was significantly reduced in high dose MA-treated animals. In addi-
tion, we assessed the number of immune cells infiltrating the tissue of the dorsal skinfold chamber by means of 
immunohistochemistry. Our analyses revealed that the number of myeloperoxidase (MPO)-positive neutrophilic 
granulocytes and CD68-positive macrophages was significantly lower in MA-treated mice after 3 h ischemia and 
24 h reperfusion when compared to controls (Fig. 5c–f).
We further analyzed the expression of the NO-producing enzyme eNOS and the heat shock protein HO-1 
within the tissue of vehicle- and MA-treated dorsal skinfold chambers. After 3 h ischemia and 3 h reperfusion, 
MA significantly induced the expression of the anti-oxidative proteins (Fig. 6a,b). Moreover, we investigated the 
effect of MA on the oxidative DNA degradation by means of 8-hydroxydeoxyguanosine (8-OHDG) staining after 
3 h ischemia and 24 h reperfusion. Of note, the number of 8-OHDG-positive cells was markedly diminished in 
MA-treated animals when compared to controls (Fig. 6c,d).
Discussion
The phytochemical MA is a pentacyclic triterpene with a broad spectrum of biological activities24. The 
anti-inflammatory action of this compound has been extensively investigated16,25. However, the effects of MA on 
leukocyte-endothelial cell interactions have not been analyzed so far. In our study, we show that MA suppresses 
I/R-induced leukocyte adhesion and transmigration into the post-ischemic tissue.
In the last decade, most studies focused on the anti-cancer activity of MA, because this compound exerts 
anti-proliferative and pro-apoptotic effects26–28. Of interest, doses of more than 100 µM MA have been shown to 
suppress cell growth and to induce apoptosis, whereas low doses of <100 µM solely affect the proliferation rate 
of tumor cells29. In this study, we assessed cell proliferation by measuring mitochondrial activity using a WST-1 
of experiments conducted in triplicate. (h) Pericytes were exposed to vehicle (DMSO) or MA (40 µM) and 
cultivated as described in (g). The cytoplasmic and nuclear localization of p65 was analyzed by Western blot. 
Bands were cropped from different parts of the same gel. (i,j) p65/α-tubulin (% of vehicle + hypoxia) (i) 
and p65/nucleolin (% of vehicle + hypoxia) (j), as assessed by quantitative analysis of Western blots (n = 5). 
Mean ± SD. *P < 0.05 vs. vehicle + hypoxia.
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assay. This assay is based on the cleavage of tetrazolium salt by mitochondrial dehydrogenases to form formazan 
in viable cells. This correlates with the number of vital cells and, thus, is frequently used for the indirect measure-
ment of cell proliferation. We found that treatment with 20–40 µM MA decreases the mitochondrial activity of 
endothelial cells. In contrast, these doses of MA did not affect the proliferation of pericytes. This contradictory 
result may be explained by the fact that pericytes exhibit a reduced proliferation rate when compared to HDMEC. 
Figure 4. Effect of MA on I/R-induced leukocyte-endothelial cell interaction. (a) Schematic illustration of the 
experimental I/R setup in vivo. (b) Intravital fluorescence microscopic images of collecting venules in dorsal 
skinfold chambers of vehicle-treated and MA (20 mg/kg)-treated mice after 3 h ischemia and 3 h reperfusion. 
The plasma marker 5% FITC-labeled dextran was used for the visualization of microvessels. Leukocytes (white 
arrows) were stained in vivo by rhodamine 6 G. Scale bar: 50 μm. (c–f) Mice with dorsal skinfold chambers were 
treated with vehicle (DMSO; white bars), low dose MA (10 mg/kg; grey bars) and high dose MA (20 mg/kg; 
black bars). Rolling leukocytes (min−1) (c), adherent leukocytes (mm−2) (d), functional capillary density (cm−1) 
(e) and macromolecular leakage (E1/E2) (f) were assessed by intravital fluorescence microscopy and computer-
assisted image analysis 19 h before and 0.5 h, 3 h and 24 h after 3 h ischemia (n = 8 per group). Mean ± SD. 
aP < 0.05 vs. −19 h (baseline) in each individual group; *P < 0.05 vs. vehicle. #P < 0.05 vs. low dose MA.
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Thus, HDMEC may be more affected by the anti-proliferative effect of MA than pericytes. In line with this view, 
Reyes et al.30 reported that MA particularly induces G0/G1 arrest in high proliferative cancer cells.
Our in vitro analyses revealed that MA dose-dependently diminishes the level of E-selectin, ICAM-1 and 
VCAM-1 on endothelial cells. These surface adhesion proteins are important for the interaction with leukocytes. 
E-selectin mediates leukocyte rolling along the microvascular endothelium31, whereas ICAM-1 and VCAM-1 are 
essential for firm leukocyte adhesion and transmigration2,32,33. Beside endothelial cells, pericytes are also crucially 
involved in the process of leukocyte extravasation3,34,35. In fact, ICAM-1 on pericytes binds to its leukocytic coun-
ter receptors lymphocyte function-associated antigen (LFA)-1 and macrophage antigen (Mac)-13,36 and, thus, 
mediates the final passage of leukocytes through the microvascular wall. Of interest, we found that hypoxia and 
reoxygenation-induced pericytic ICAM-1 expression is also reduced by MA. Similar effects of MA have also been 
reported for other cell types. Park et al.37 showed a reduced migration, invasion and adhesion of MA-treated 
human prostate cancer cells, which was caused by a diminished expression of ICAM-1 and VCAM-137. They 
further found that this was mediated by a reduced activity of Akt and extracellular signal-related kinases (ERK)37. 
In addition, Li et al.16 demonstrated that MA inhibits cytokine-induced ICAM-1 expression in pancreatic cancer 
cells and, thus, alleviates their invasive ability. Taken together, these results indicate that MA acts as a pleiotropic 
compound targeting the expression of multiple surface adhesion proteins on different cell types.
Hypoxia activates different signaling pathways38, including NFκB5–7. Furthermore, it has been reported that 
MA inhibits the NFκB pathway by preventing IκBα phosphorylation, which, in turn, reduces nuclear localiza-
tion, phosphorylation and DNA-binding of p6516,25. Accordingly, we investigated whether the herein observed 
reduced expression of the adhesion molecules E-selectin, ICAM-1 and VCAM-1 is mediated by the inhibition of 
NFκB. By means of immunofluorescence microscopy we could demonstrate that MA inhibits the shuttling of the 
transcription factor p65 into the nucleus of both endothelial cells and pericytes. In addition, it has been shown 
that MA supresses the activity of PKC19,39. This kinase is also crucially involved in hypoxia-induced signaling40,41. 
In addition, PKC is upstream of the NFκB pathway42 and, thus, it can be speculated that the downregulatory effect 
of MA on adhesion molecule expression is caused by a dual inhibition of NFκB signaling and PKC activity.
Our in vitro results were confirmed in the dorsal skinfold chamber model, which is suitable for the analysis of 
leukocyte-endothelial cell interactions under inflammatory conditions43,44. Of interest, we detected a higher num-
ber of rolling leukocytes in post-ischemic venules of MA-treated mice when compared to controls. This may be 
explained by our observation that MA reduces the expression of E-selectin on endothelial cells. E-selectin medi-
ates slow leukocyte rolling and contributes in some way to leukocyte adhesion. This reduces leukocytes from the 
rolling pool. Indeed, Kunkel et al.31 showed that loss of E-selectin increases the rolling of leukocytes in microves-
sels. Moreover, we found that venular leukocyte adhesion is significantly diminished after MA treatment. In line 
with our in vitro results, additional Western blot analyses demonstrated that this was due to a reduced endothelial 
expression of ICAM-1 and VCAM-1.
Studies have reported that MA is capable of reducing pro-inflammatory cytokines, including TNF-α and 
interleukin (IL)-618,19. These cytokines stimulate the recruitment of different immune cells into ischemic tis-
sue45,46. Therefore, we further assessed the number of MPO-positive neutrophilic granulocytes and CD68-positive 
macrophages infiltrating the tissue of the dorsal skinfold chamber by means of immunohistochemistry. We found 
that the number of these cells was significantly lower in MA-treated animals when compared to vehicle-treated 
controls.
Besides its inhibitory action on cytokine release, MA has also been shown to interact with secretory phospholi-
pase A2-IIA (sPLA2-IIA), one of the key enzymes causing lipoprotein modification and vascular inflammation47. 
−19 h +0.5 h +3 h  + 24 h
diameter (µm)
vehicle 26.0 ± 3.4 32.3 ± 2.2a 30.9 ± 2.4a 31.8 ± 4.0a
MA (10 mg/kg) 22.9 ± 2.9 29.7 ± 3.6a 28.1 ± 2.3a 26.7 ± 1.5a
MA (20 mg/kg) 25.5 ± 2.8 32.3 ± 2.2a 31.8 ± 2.9a 30.3 ± 2.8a
centerline RBC velocity (µm/s)
vehicle 308.8 ± 142.4 186.2 ± 117.8 227.9 ± 127.6 243.6 ± 129.1
MA (10 mg/kg) 270.4 ± 101.4 265.4 ± 175.5 239.5 ± 134.2 186.6 ± 70.2
MA (20 mg/kg) 533.8 ± 166.9 463.9 ± 184.5 388.1 ± 147.1 348.8 ± 117.7
volumetric blood flow (pL/s)
vehicle 103.0 ± 57.5 95.4 ± 58.1 109.7 ± 57.9 110.7 ± 60.0
MA (10 mg/kg) 70.4 ± 32.4 118.2 ± 59.5 93.6 ± 37.2 57.8 ± 35.0
MA (20 mg/kg) 170.7 ± 66.2 234.8 ± 85.4 186.6 ± 34.3 158.5 ± 47.4
wall shear rate (s−1)
vehicle 93.1 ± 53.0 45.8 ± 28.4 61.2 ± 33.1 65.9 ± 43.2
MA (10 mg/kg) 94.9 ± 39.4 71.6 ± 41.2 68.4 ± 21.9 55.8 ± 23.8
MA (20 mg/kg) 170.1 ± 53.9 116.2 ± 40.2 100.5 ± 34.4 88.2 ± 20.9
Table 1. Diameter (µm), centerline RBC velocity (µm/s), volumetric blood flow (pL/s) and wall shear rate (s−1) 
of postcapillary and collecting venules in dorsal skinfold chambers of vehicle-treated, low dose MA (10 mg/kg)-
treated and high dose MA (20 mg/kg)-treated mice 19 h before as well as 0.5 h, 3 h and 24 h after ischemia (n = 8 
per group). Mean ± SD. aP < 0.05 vs. −19 h (baseline) in each individual group.
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Figure 5. Effect of MA on ICAM-1 and VCAM-1 expression and immune cell recruitment in I/R-exposed 
tissue. (a,b) The expression of ICAM-1 (a) and VCAM-1 (b) in extracts of dorsal skinfold chamber tissue from 
vehicle-treated (DMSO; white bars) and MA (20 mg/kg)-treated animals (3 h after reperfusion; black bars) 
was analyzed by Western blot. Bands were cropped from different parts of the same gel. ICAM-1/β-actin (% 
of vehicle) (a) and VCAM-1/β-actin (% of vehicle) (b), as assessed by quantitative analysis of Western blots 
(n = 3). Mean ± SD. *P < 0.05 vs. vehicle. (c,e) Immunohistochemical detection of transmigrated MPO-positive 
neutrophilic granulocytes (black arrows, c) and CD68-positive macrophages (black arrows, e) in dorsal skinfold 
chambers of vehicle-treated and MA (20 mg/kg)-treated animals after 3 h ischemia and 24 h reperfusion. Scale 
bar: 50 µm. (d,f) Transmigrated MPO-positive neutrophilic granulocytes (d) and CD68-positive macrophages 
(f) (per HPF) in dorsal skinfold chambers of vehicle-treated (DMSO; white bars), low dose MA (10 mg/
kg)-treated (grey bars) and high dose MA (20 mg/kg)-treated mice (black bars) were assessed by quantitative 
analysis of immunohistochemical sections (n = 8 per group). Mean ± SD. *P < 0.05 vs. vehicle.
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Of interest, Yap et al.48 reported that MA suppresses sPLA2-IIA-mediated monocyte migration. Hence, we sug-
gest that this may have additionally contributed to the herein observed inhibition of macrophage recruitment in 
the dorsal skinfold chamber tissue of MA-treated animals.
In light of the fact that MA exhibits an anti-oxidative activity17,21,22, we further analyzed the expression of the 
NO-producing enzyme eNOS within the tissue of vehicle- and MA-treated dorsal skinfold chambers. We found 
that high doses of MA significantly increase the expression of eNOS when compared to controls. These results are 
in line with Li et al.22 reporting an elevated activity of eNOS in MA-treated endothelial cells. NO is an important 
signaling molecule, which is involved in the regulation of HO-1 gene expression49. Moreover, it is known that MA 
induces the nuclear accumulation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), 
which, in turn, transcriptionally activates the expression of HO-121. Accordingly, we also measured an increased 
expression of this heat shock protein in MA-treated animals. The anti-oxidative activity of MA was further ver-
ified by a significantly reduced number of 8-OHDG-positive cells within the dorsal skinfold chamber tissue of 
MA-treated animals, indicating that the phytochemical compound prevents oxidative DNA damage.
Finally, although not further investigated in the present study, it may be speculated that the herein observed 
effects of MA are partially mediated by reversible blockade of the mitochondrial respiratory chain as another 
potential mechanism of action. In fact, several studies could demonstrate that the suppression of electron 
Figure 6. Effect of MA on anti-oxidative enzyme expression and oxidative DNA damage. (a,b) The expression 
of eNOS (a) and HO-1 (b) in extracts of dorsal skinfold chamber tissue from vehicle-treated (DMSO; white 
bars) and MA (20 mg/kg)-treated animals (black bars) after 3 h ischemia and 3 h reperfusion was analyzed by 
Western blot. Bands were cropped from different parts of the same gel. eNOS/β-actin (% of vehicle) (a) and HO-
1/β-actin (% of vehicle) (b), as assessed by quantitative analysis of Western blots (n = 3). Mean ± SD. *P < 0.05 
vs. vehicle. (c) Immunohistochemical detection of 8-OHDG-positive cells (white arrows) in dorsal skinfold 
chambers of vehicle-treated and MA (20 mg/kg)-treated animals after 3 h ischemia and 24 h reperfusion. 
Scale bar: 75 µm. Dashed boxes (lower panel) show 8-OHDG-stained cells in a higher magnification. Scale 
bar: 10 µm. (d) 8-OHDG-positive cells (per HPF) in dorsal skinfold chambers of vehicle-treated (DMSO; 
white bar), and high dose MA (20 mg/kg)-treated mice (black bar) were assessed by quantitative analysis of 
immunohistochemical sections (n = 8 per group). Mean ± SD. *P < 0.05 vs. vehicle.
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transport during ischemia by complex I inhibitors protects mitochondria against ischemic damage and attenu-
ates the mitochondrial release of ROS during reperfusion50–52. To test our hypothesis it should first be clarified 
whether complex I is actually a target of MA by determining the compound’s binding affinity to the hydrophobic 
site of the enzyme and its inhibitory action on enzyme activity. If this succeeds, it would be interesting to compare 
in additional studies the protective effectiveness of MA against I/R-induced inflammation and tissue injury with 
that of conventional complex I inhibitors.
There is considerable interest for the application of MA in clinical practice. MA has already been shown to 
protect cortical neurons against oxygen and glucose deprivation damage by inhibition of caspase cleavage and 
ROS formation53. More recently, Quian et al.54 reported that MA extends the therapeutic window of the NMDA 
receptor antagonist MK-801 in a model of ischemic stroke. The present study now demonstrates that MA inhibits 
I/R-induced inflammation by downregulation of NFκB-mediated surface adhesion molecule expression. Our 
results further show that MA treatment prevents oxidative DNA damage. This anti-oxidative activity of MA may 
have markedly contributed to the suppression of NFκB signaling. Indeed, ROS can activate NFκB through alter-
native IκBα phosphorylation and influence the DNA binding properties of the NFκB proteins themselves55.
Considering the fact that MA exhibits a favorable safety profile in toxicity studies13,56, these findings indicate 
that this phytochemical compound may represent an attractive candidate for the development of novel adjuvant 
treatment strategies against I/R-induced tissue injury.
Methods
Chemical and biological reagents. Endothelial cell basal medium and pericyte growth medium were 
purchased from PromoCell (Heidelberg, Germany). Dulbecco’s modified Eagle’s medium (DMEM) low glucose 
was from Lonza (Cologne, Germany). Human TNF-α was from Provitro (Berlin, Germany). MA was purchased 
from Santa Cruz Inc. (Heidelberg, Germany). Fluorescein isothiocyanate-labeled dextran 150,000, rhodamine 
6 G and peroxidase-labeled-streptavidin were purchased from Sigma-Aldrich (Munich, Germany). Mayer’s 
hemalaun solution was from Merck (Darmstadt, Germany). 3-Amino-9-ethylcarbazole was obtained from 
Abcam (Cambridge, UK). Ketamine (Ursotamin) was from Pharmacia GmbH (Erlangen, Germany) and xylazine 
(Rompun) was from Bayer (Leverkusen, Germany).
Antibodies. The anti-p65 antibody (sc-372), the anti-PDGFR-β antibody (sc-432), the anti-β-actin anti-
body (sc-517582) and the anti-NG2 antibody (sc-166251) were obtained from Santa Cruz Inc. The antibodies 
anti-CD54 (ICAM-1) (555511), anti-CD62E (E-selectin) (551145), anti-CD106 (VCAM-1) (555647) and IgG1-κ 
Isotype Control (555749) were purchased from BD Biosciences (Heidelberg, Germany). Peroxidase-labeled 
anti-rabbit antibody (NIF 824) and peroxidase-labeled anti-mouse antibody (NIF 825) were obtained from GE 
Healthcare (Freiburg, Germany). The anti-HO-1 antibody (ADI-SPA-895) was from Enzo Life Sciences (Lörrach, 
Germany). The anti-α-tubulin antibody (ab56676), the anti-myeloperoxidase (MPO) antibody (ab9535), the 
anti-ICAM-1 antibody (ab124760), the anti-8-OHDG antibody (ab10802), the anti-eNOS antibody (ab5589), 
the anti-VCAM-1 antibody (ab134047), the anti-CD68 antibody (ab1252212) and the secondary biotinylated 
goat anti-rabbit antibody (ab64256) were purchased from Abcam.
Cell culture. Human placenta-derived pericytes and HDMEC were purchased from PromoCell and culti-
vated at 37 °C under a humidified 95/5% (vol/vol) mixture of air and CO2. Cells were passaged at a split ratio of 
1:3 after reaching confluence. All experiments were carried out with confluent cells between the third and seventh 
passage.
Hypoxia and reoxygenation. HDMEC and pericytes were treated with different concentrations of MA 
or vehicle (DMSO) and cultivated in DMEM (low glucose without fetal calf serum) under hypoxic conditions 
(95% N2, 4% CO2 and 1% O2) for 16 h. Afterwards, the medium was replaced by endothelial cell basal medium or 
pericyte growth medium and the cells were cultivated for additional 4 h or 24 h under normoxia (95% air and 5% 
CO2) prior to the different analyses.
WST-1 assay. A WST-1 assay (Roche, Mannheim, Germany) was used to evaluate the mitochondrial activity 
of HDMEC and pericytes as described previously in detail44.
LDH assay. A LDH assay (Cytotoxicity Detection KitPLUS, Roche) was used to analyze the viability of 
HDMEC and pericytes as previously described in detail44.
Annexin V/PI assay. Apoptotic and necrotic cells were detected by an Annexin V/PI detection kit 
(Invitrogen, Karlsruhe, Germany). Briefly, after hypoxia and reoxygenation cells were incubated at room tem-
perature with Annexin V and PI for 30 min. The mean fluorescence intensity (MFI) of 5,000 cells was analyzed 
in the FL-1 and FL-2 channel by a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) using the 
CellQuest software.
Western blot analysis. Cytoplasmic and nuclear extracts from HDMEC and pericytes as well as dorsal 
skinfold chamber tissue extracts were generated as described previously in detail57. Proteins of cell extracts were 
separated through a 12.5% SDS polyacrylamide gel and transferred onto a polyvinylidene difluoride (PVDF) mem-
brane. The membrane was incubated in 5% dry milk in phosphate-buffered saline (PBS) (0.1% Tween20) for 1 h 
and exposed to anti-p65, anti-ICAM-1, anti-VCAM-1, anti-eNOS, anti-HO-1, anti-β-actin, anti-α-tubulin and 
anti-nucleolin antibodies, which were diluted (1:500) in PBS (0.1% Tween20) containing 1% dry milk. After incuba-
tion of the membrane with a peroxidase-coupled secondary antibody (anti-rabbit 1:30,000 or anti-mouse 1:10,000) 
for 1 h, protein expression was detected by means of luminol-enhanced chemiluminescence (ECL; GE Healthcare).
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Flow cytometry. HDMEC and pericytes were cultivated under hypoxia and reoxygenation in medium sup-
plemented with MA or vehicle (DMSO). Subsequently, the cells were washed in PBS and harvested by incubation 
with trypsin/EDTA (0.25% (w/v) trypsin, 0.02% EDTA) for 5 min at 37 °C. Subsequently, the cells were incubated 
with the phycoerythrin (PE)-labeled primary antibodies E-Selectin, ICAM-1, VCAM-1 and the PE-labeled IgG 
control antibodies for 30 min at room temperature. Then, HDMEC and pericytes were washed in PBS and the 
MFI of 5,000 cells was analyzed in the FL-2 channel by a FACScan flow cytometer (Becton Dickinson) using the 
CellQuest software.
Immunofluorescence microscopy. HDMEC and pericytes were seeded on coverslips and treated with 
different concentrations of MA or vehicle (DMSO) and exposed to hypoxia and reoxygenation. Then, the cells 
were fixed in PBS (3.7% formalin) for 10 min and subsequently permeabilized in PBS (0.2% Triton X-100) for 
30 min. Afterwards, the cells were blocked in PBS (2% BSA) for further 30 min at room temperature. HDMEC 
and pericytes were incubated with anti-p65 antibodies (1:50) and the secondary anti-rabbit antibodies (1:250). 
Subsequently, the cells were sealed with mounting media and analyzed by fluorescence microscopy (BX60; 
Olympus, Hamburg, Germany).
Animals. In this study, male and female BALB/c mice with a body weight of 20–30 g were used. They were 
bred and housed in open cages in the conventional animal facility of the Institute for Clinical & Experimental 
Surgery (Saarland University, Germany). Housing was performed in a temperature-controlled environment 
under a 12 h/12 h light-dark cycle. The animals had free access to standard pellet chow (Altromin, Lage, Germany) 
and water. The experiments were approved by the local governmental animal protection committee (Landesamt 
für Verbraucherschutz, Abteilung C Lebensmittel- und Veterinärwesen, Saarbrücken, Germany; permit number: 
15/2014) and were conducted in accordance with the European legislation on protection of animals (Guide line 
2016/63/EU) and the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (http://
oacu.od.nih.gov/regs/index.htm. Eighth Edition; 2011).
Dorsal skinfold chamber model. The dorsal skinfold chamber served as model to analyze the effects of 
MA on I/R-induced inflammation. For the implantation of the chamber, the mice were anesthetized by intraperi-
toneal (i.p.) injection of ketamine (75 mg/kg) and xylazine (15 mg/kg). The chamber was prepared as described 
previously in detail58. In brief, two symmetrical titanium frames were implanted on the extended dorsal skinfold 
of the animals. One layer of the skin was removed in a circular area of 15 mm in diameter and the remaining lay-
ers consisting of the cutis, subcutaneous tissue and striated skin muscle were covered with a glass coverslip. After 
surgery, mice were allowed to recover for 72 h.
Ischemia was induced as previously described in detail59. Briefly, the striated muscle tissue of the chamber was 
gently pressed for 3 h against the cover slip of the observation window using an adjustable screw. The pressure of 
40 mmHg was sufficient to occlude all arteriolar, capillary and venular blood vessels within the chamber, thus, 
garnished complete ischemia. Subsequently, the screw was removed to restore blood perfusion. To investigate 
the effect of MA on leukocytic inflammation, 8 animals were treated with 10 mg/kg MA or 20 mg/kg MA i.p. 
(dissolved in 50 µL DMSO) 19 h and 1 h before the induction of ischemia. As controls we used 8 vehicle-treated 
mice. For Western blot analyses of the dorsal skinfold chamber tissue after 3 h ischemia and 3 h reperfusion, 
additional animals were treated with 20 mg/kg MA i.p. (n = 3) or vehicle (n = 3) 19 h and 1 h before the induction 
of ischemia.
Intravital fluorescence microscopy. For intravital fluorescence microscopy the animals received a ret-
robulbary i.v. injection of 0.05 mL 5% FITC-labeled dextran 150,000 to enhance the contrast of blood-perfused 
microvessels. Moreover, they received 0.05 mL 0.1% rhodamine 6 G i.v. for in situ staining of leukocytes. 
Subsequently, the mice were fixed on a plexiglas stage and the dorsal skinfold chamber was horizontally posi-
tioned under a Zeiss microscope (Zeiss, Oberkochen, Germany) equipped with a 100 W mercury lamp attached 
to a blue (excitation wavelength: 450–490 nm/emission wavelength: >515 nm) and green (530–560 nm/>585 nm) 
filter block. The microscopic images were recorded by a charge-coupled device video camera (FK6990; Pieper, 
Schwerte, Germany) connected to a monitor (Trinitron; Sony, Tokyo, Japan) and DVD system (DVD-HR775; 
Samsung, Eschborn, Germany)60.
The microscopic images were analyzed by means of the off-line analysis system CapImage (Zeintl, Heidelberg, 
Germany). Leukocyte-endothelial cell interactions, microhemodynamic parameters, functional capillary density 
and macromolecular leakage were assessed in 8 randomly selected venules per chamber. Measurements were 
performed under baseline conditions before injection of MA or vehicle 19 h prior to ischemia as well as 0.5 h, 3 h 
and 24 h during post-ischemic reperfusion of the tissue43,59. Finally, the dorsal skinfold chamber tissue was used 
for additional immunohistochemical analyses.
Immunohistochemistry. Formalin-fixed specimens of the chamber tissue were embedded in par-
affin for the cutting of 3 µm-thick sections. The sections were stained with a polyclonal rabbit anti-mouse 
antibody against the neutrophilic granulocyte marker MPO or against the macrophage marker CD68 fol-
lowed by a biotinylated secondary goat anti-rabbit IgG antibody. The biotinylated antibody was detected by 
peroxidase-labeled-streptavidin. 3-Amino-9-ethylcarbazole was used as chromogen. The sections were coun-
terstained with Mayer’s hemalaun. As negative controls we used sections solely incubated with the secondary 
antibody. MPO-positive and CD68-positive cells were counted in 10 high power fields (HPF) per section and are 
given as cells/HPF. For the detection of 8-OHDG, the sections were stained with a polyclonal goat anti-mouse 
antibody against anti-8-OHDG followed by a secondary coupled fluorescence antibody. As negative controls we 
used sections solely incubated with the secondary antibody. 8-OHDG-positive cells were counted in 10 HPF per 
section and are given as cells/HPF.
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statistical analysis. After testing the data for normal distribution and equal variance, differences between 
two groups were analyzed by the unpaired Student’s t-test and differences between multiple groups were analyzed 
by one-way ANOVA followed by the appropriate post hoc test, including the correction of the alpha error accord-
ing to Bonferroni’s probabilities (SigmaPlot 13.0; Jandel Corporation, San Rafael, CA, USA). To test for time 
effects in individual groups, ANOVA for repeated measures was applied followed by Bonferroni-t-test. All values 
are expressed as mean ± standard deviation (SD). Statistical significance was accepted for P < 0.05.
Data Availability
All data generated or analyzed during this study are included in this published article
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